

Regulatory Updates Health Sciences Authority Singapore

Wong Woei Jiuang
Director, Medical Devices Branch,
Health Sciences Authority, Singapore

Background

Pre-market Consultation (PMC) Scheme

- Medical Device Development Consultation
- Medical Device Pre-submission Consultation

Priority Review Scheme

- Qualification Criteria
- Priority Review Scheme Routes

Background



Support Innovation and Device Development Locally

- Engage researchers and developers
- Enable better understanding of regulatory requirements at early stage of device development



Facilitate timely access for Medical Devices that demonstrate the potential to address unmet clinical needs



To differentiate HSA as a trusted regulatory leader to help local enterprises expand overseas

HSA's Initiatives

1. Pre-Market Consultation Scheme

Support innovation and device development by ensuring devices are in line with regulatory requirements

2. Priority Review Scheme

Facilitate timely access for devices that address unmet clinical needs

To provide support through the device development lifecycle

DISCOVERY + IDEATION

DEVELOP + PRE-CLINICAL

CLINICAL

REGULATORY SUBMISSION

PRODUCT LAUNCH



Support innovation and device development

MEDICAL DEVICE PRE-MARKET CONSULTATION (PMC) SCHEME

Pre-Market Consul

Channel for stakeholders to seek regulatory advice during medical device development phase to align with regulatory requirements.

Medical Device Development Consultation

DISCOVERY + IDEATION

DEVELOP +
PRECLINICAL

CLINICAL

REGULATORY SUBMISSION

Medical Device Pre-submission Consultation

Channel for stakeholders to seek feedback on their device dossier, prior to pre-market submission in terms of completeness and appropriateness of supporting documents.

PRODUC T LAUNCH

Channel for stakeholders to seek regulatory advice during medical device development phase to align with regulatory requirements.

Medical Device Development Consultation

SCOPE: Clarification on regulatory requirements applicable to the device in development, which may include

- Regulatory requirements
- -Device claims
- -Safety / Performance studies
- -Sterility
- -Biocompatibility
- -Risk management
- -Clinical trials
- Regulatory strategy

DISCOVERY + IDEATION

DEVELOP +
PRECLINICAL

CLINICAL

REGULATORY SUBMISSION

PRODUC T LAUNCH

1. Medical Device Development Consultation

Who

Medical device developers, researchers When

Any time during device development

What

For 1 specific device or a group of devices intended to be used together

What it is not

Endorsement of any validation plans, test protocols and/or results that were discussed in the consultation

Does not guarantee approval or marketing clearance

Not meant to be an iterative process

SCOPE: Seek feedback on the device dossier, in accordance to prescribed Common Submission Dossier Template (CSDT) guidance template, which may include

- Risk Classification
- •Registration Route
- Grouping
- Technical & administrative documents

Medical Device Pre-submission Consultation

Channel for stakeholders to seek feedback on their device dossier, prior to pre-market submission in terms of completeness and appropriateness of supporting documents.

DISCOVERY + DEVELOP + PRE-CLINICAL

CLINICAL

REGULATORY SUBMISSION

PRODUC T LAUNCH

2. Medical Device Pre-Submission Consultation

Who

Stakeholders submitting medical devices for registration locally When

Before submission of pre-market application to HSA What

Devices to be registered in 1 single pre-market application

What it is not

Not a scientific evaluation of the device

Does not guarantee regulatory approval or marketing clearance



MDRF International Medical Device Regulators Forum

Summary of Submission Requirements (Class B)

	Documentary Requirements	Full	Abridged	EBR-1 and EBR-2	IBR
1	Letter of Authorisation	✓	✓	✓	✓
2	Annex 2 List of Configurations	✓	✓	✓	✓
3	Proof of reference agency's approval(s)		✓	✓	✓
4	Proof of marketing history in the reference agencies' jurisdictions e.g. invoice with date, proof of sale or a declaration on marketing history			√ Only required	√
5	Declaration of no safety issues globally			for EBR-1	✓
6	Executive Summary	✓	✓	✓	✓
7	Essential Principles Checklist and Declaration of Conformity	✓	·	✓	
8	Device Description	✓	✓	✓	✓
9	Design verification and validation documents including: • Preclinical studies e.g. physical test data, biocompatibility studies, animal studies and software verification and validation studies • Metrological requirements • Sterilisation validation (if applicable) • Shelf-life studies and projected useful life	Detailed reports ¹	✓ Summary ²	√ Summary 2	Sterilisation validation for Sterile device only ³
10	Clinical Evidence ⁴	If applicable			
11	Proposed Device Labelling ⁴	✓	✓	✓	✓
12	Risk Analysis	✓	If applicable		
13	Manufacturer Information (site's name and address)	✓	✓	✓	✓
14	Proof of QMS- Eg: ISO13485 Certificate, Conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	~	1	1	✓
15	Manufacturing Process - Flow Chart	✓			

Summary of Submission Requirements (Class C and D)

1 Letter of Authorization		Document Requirements		Abridged	ECR-1 and ECR-2	EDR
Proof of reference agency's approval(s) Proof of marketing history in the reference agencies' jurisdictions e.g. invoice with date, proof of sale or a declaration on marketing history Declaration of no safety issues globally Executive Summary Essential Principles Checklist and Declaration of Conformity Device Description Design verification and validation documents including: Preclinical studies e.g. physical test data, blocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable) Shelf-life studies and projected useful life Clinical Evidence Proposed Device Labelling Manufacturer information (site's name and address) Proof of CMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169		Letter of Authorization	· ·		✓	~
Proof of marketing history in the reference agencies' jurisdictions e.g. invoice with date, proof of sale or a declaration on marketing history Declaration of no safety issues globally Executive Summary Essential Principles Checklist and Declaration of Conformity Device Description Design verification and validation documents including: Preclinical studies e.g. physical test data, biocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable) Shelf-life studies and projected useful life Clinical Evidence Proposed Device Labelling Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	2	Annex 2 List of Configurations	*	✓	✓	✓
agencies' jurisdictions e.g. invoice with date, proof of sale or a declaration on marketing history Declaration of no safety issues globally Executive Summary Essential Principles Checklist and Declaration of Conformity Design verification and validation documents including: Preclinical studies e.g. physical test data, blocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable) Shelf-life studies and projected useful life Clinical Evidence Risk Analysis Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	3	Proof of reference agency's approval(s)		✓	✓	✓
Essential Principles Checklist and Declaration of Conformity Besign verification and validation documents including: Preclinical studies e.g. physical test data, biocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable) Shelf-life studies and projected useful life Clinical Evidence Proposed Device Labelling Risk Analysis Manufacturer information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	4	agencies' jurisdictions e.g. invoice with date, proof of sale or a declaration on marketing			Only required	
Essential Principles Checklist and Declaration of Conformity Bessential Principles Checklist and Declaration of Conformity Design verification and validation documents including: Preclinical studies e.g. physical test data, biocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable) Shelf-life studies and projected useful life Clinical Evidence Proposed Device Labelling Risk Analysis Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	5	Declaration of no safety issues globally	ration of no safety issues globally			
Declaration of Conformity Declaration Design verification and validation documents including: Preclinical studies e.g. physical test data, biocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable) Shelf-life studies and projected useful life Clinical Evidence Proposed Device Labelling Risk Analysis Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	6	Executive Summary	ecutive Summary		✓	✓
Design verification and validation documents including: • Preclinical studies e.g. physical test data, blocompatibility studies, animal studies and software verification and validation studies • Metrological requirements • Sterilisation validation (if applicable) • Shelf-life studies and projected useful life 10 Clinical Evidence 11 Proposed Device Labelling 12 Risk Analysis Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	7				✓	*
Including: Preclinical studies e.g. physical test data, blocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable) Shelf-life studies and projected useful life Clinical Evidence Proposed Device Labelling Risk Analysis Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	8	Device Description	✓	✓	✓	✓
11 Proposed Device Labelling 12 Risk Analysis Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	9	Preclinical studies e.g. physical test data, biocompatibility studies, animal studies and software verification and validation studies Metrological requirements Sterilisation validation (if applicable)		√ Summary ²	Summary ²	-
12 Risk Analysis Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	10	Clinical Evidence	✓	✓	✓	✓
13 Manufacturer Information (site's name and address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	11	Proposed Device Labelling	✓	✓	✓	✓
address) Proof of QMS – E.g. ISO13485 certificate, conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169	12	Risk Analysis	✓	✓	✓	~
14 conformity to US FDA Quality System Regulations or Japan MHLW Ordinance 169 ✓ ✓ ✓	13		✓	✓	✓	~
15 Manufacturing process – Flow chart ✓ ✓ ✓ ✓	14	conformity to US FDA Quality System	~	√	~	*
	15	Manufacturing process – Flow chart	✓	✓	✓	✓

Pre-Market Consultation (PMC) Scheme

Following are examples of queries which do not require PMC:

- •General questions regarding registration procedures or documentary requirements for product registration.
- •Clarification on the guidance documents on the website.
- •To seek advice on the risk classification or grouping.
- During the review process of a product registration.
- •To appeal a decision made during pre-market submission.

These enquiries can be sent as general enquiries / using dedicated enquiry form(s) to HSA_MD_Info@hsa.gov.sg, or to contact officer in charge for clarification related to specific application.

Facilitate timely access for Medical Devices that demonstrate the potential to address unmet clinical needs

MEDICAL DEVICE PRIORITY REVIEW SCHEME

Medical devices* to be registered via FULL Evaluation Route



Route 2

Qualification Criteria

- Falls und fatthe 5 healthcare area
 - Cancer
 - Diabetes
 - Ophthalmologic dist
 - Cardiovascula ses
 - Infectious d

Designation validated to

Intended for a medical purpose with no existing alternative treatment or means of diagnosis

OR

tes a breakthrough tes bat provides a clinically meaningful to be a provided as a clinically legally marketed technology

Route 1

^{*} Class A and devices incorporating registrable medicinal/ therapeutic products are not eligible for the Priority Review Scheme.

	TAT (in working days)		Evaluation Fee (\$)		
Risk Class	Route 1 & 2		Route 1	Route 2	
Oldss	25% reduction by mid 2018	35% reduction by end 2019	15% increase over current fee	50% increase over current fee	
Class B (FULL)	120	105	4,100	5,300	
Class C (FULL)	165	145	6,600	8,600	
Class D (FULL)	235	205	13,200	17,100	



Upcoming Documents

- Update to the Guidance on Preparation of the ASEAN CSDT* for Medical Devices and In Vitro Diagnostics (IVDs)
- Registration and listing of IVD analysers and instruments

Thank you!